Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Bert Roland Kari Junno | M | 58 |
Aptahem AB
 Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
| Knut Mikael Ingolf Lindstam | M | 58 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 10 Jahre |
| Rajeev Ahuja | M | - |
University of Uppsala
| - |
| Luiza Jedlina | M | - |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 10 Jahre |
| Theresa Comiskey Olsen | F | 61 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
| Anders R. Hallberg | M | 79 |
University of Uppsala
| - |
| Carl-Hendrik Heldin | M | 72 |
University of Uppsala
| 32 Jahre |
| Margareta Elisabeth Björk | M | 62 |
University of Uppsala
| - |
| Angelica Loskog | M | 51 |
University of Uppsala
| - |
| Ola Skanung | M | 60 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
| Ulf Bertil Olof Göransson | M | 54 |
University of Uppsala
| - |
| Lars Thomander | M | 77 |
University of Uppsala
| - |
| Sverker Ljunghall | M | - |
University of Uppsala
| - |
| Bengt Westermark | M | 79 |
University of Uppsala
| 38 Jahre |
| Hilpi Rautelin | M | 63 |
University of Uppsala
| 16 Jahre |
| Johan Olof Kämpe | M | 68 |
University of Uppsala
| 25 Jahre |
| Eva Ursula Hultqvist Bengtsson | M | 64 |
University of Uppsala
| - |
| Peter von Ehrenheim | M | 69 |
University of Uppsala
| - |
| Maria Ekblad | F | - |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 2 Jahre |
| Per Gunningberg | M | 71 |
University of Uppsala
| - |
| Ingela Hallberg | M | 69 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 2 Jahre |
| Ingemar Kihlström | M | 72 |
University of Uppsala
| - |
| Marie-Louise Fjaellskog | M | 59 |
University of Uppsala
| 16 Jahre |
| Niklas Dahl | M | - |
University of Uppsala
| 24 Jahre |
| Magnus Essand | M | 60 |
University of Uppsala
| 15 Jahre |
| Suzanne Kilany | F | - |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
| Anne Ramberg | F | - |
University of Uppsala
| - |
| Per Matsson | M | 70 |
University of Uppsala
| - |
| Åsa Kornfeld | F | - |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
| Håkan Gunnar Engqvist | M | 52 |
University of Uppsala
| - |
| Karl Johan Anders Wall | M | 60 |
University of Uppsala
| - |
| Mathias Hallberg | M | 53 |
University of Uppsala
| - |
| Ernst Åke Bertil Karlmark | M | 86 |
University of Uppsala
| - |
| Jan Nilsson | M | 56 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
| Lars Ture Pettersson | M | 70 |
University of Uppsala
| - |
| Rolf Larsson | M | - |
University of Uppsala
| - |
| Gustav Ingemar Kihlström | M | 71 |
University of Uppsala
| - |
| Jan Thorell | M | - |
University of Uppsala
| - |
| Marek Kwiatkowski | M | 74 |
University of Uppsala
| - |
| Alf Gunnar Martin Nicklasson | M | 69 |
University of Uppsala
| - |
| Jonas Göran Ekblom | M | 59 |
University of Uppsala
| - |
| Bengt Gerdin | M | 77 |
University of Uppsala
| 30 Jahre |
| Margot Gunilla Fransson | M | 64 |
University of Uppsala
| - |
| Nils Martin Malmsten | M | - |
University of Uppsala
| - |
| Rolf Larsson | M | - |
University of Uppsala
| - |
| Ulla Cristina Glad | M | 72 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 8 Jahre |
| Mats Bo Johan Nilsson Bernitz | M | 54 |
University of Uppsala
| 21 Jahre |
| Lars Harald Baltzer | M | 73 |
University of Uppsala
| - |
| Ulla Helena Danielson | M | - |
University of Uppsala
| 22 Jahre |
| Johan Stenberg | M | - |
University of Uppsala
| - |
| Claes Tomas Post | M | 74 |
University of Uppsala
| 36 Jahre |
| Anders Wilhelmson | M | - |
University of Uppsala
| - |
| Andreas Waber | M | - |
University of Uppsala
| - |
| Knut Lars Carl Wiklund | M | 81 |
University of Uppsala
| - |
| Lars Bohlin | M | 76 |
University of Uppsala
| - |
| Bo Walter Wennström | M | 70 |
University of Uppsala
| - |
| Per Christer Folke Lundberg | M | 81 |
University of Uppsala
| - |
| Ingrid Westin Wallinder | F | 67 |
University of Uppsala
| - |
| Jonas Rastad | M | 74 |
University of Uppsala
| - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Tina Persson | M | 59 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
| Ulf Björklund | M | 68 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
| Daniel Ketema | M | - |
University of Uppsala
| 6 Jahre |
| Alex Basu | M | - |
University of Uppsala
| 9 Jahre |
| Olof Löfving | M | - |
University of Uppsala
| 5 Jahre |
| Charbel Altunkaynak | M | - |
University of Uppsala
| 5 Jahre |
| Iliam Barkino | M | - |
University of Uppsala
| 5 Jahre |
| Kjell Göran Stenberg | M | 72 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 6 Jahre |
| Carola Elisabet Lemne | M | 66 |
University of Uppsala
| 4 Jahre |
| Hanna Wingren | F | - |
University of Uppsala
| 5 Jahre |
| Martin Ulinder | M | - |
University of Uppsala
| 3 Jahre |
| Louise Tilja | F | - |
University of Uppsala
| 3 Jahre |
| Diane Carolus | F | - |
University of Uppsala
| 1 Jahre |
| Hanna Risberg | F | - |
University of Uppsala
| 5 Jahre |
| Martina Böhme | F | - |
University of Uppsala
| 5 Jahre |
| Isabel Starkebo | F | - |
University of Uppsala
| 4 Jahre |
| Hekla Parker | F | - |
University of Uppsala
| 2 Jahre |
| Joel Hellrup | M | 41 |
University of Uppsala
| 3 Jahre |
| Oscar Östlin | M | - |
University of Uppsala
| 4 Jahre |
| Olivia Bergkvist | F | - |
University of Uppsala
| 3 Jahre |
| Josephine Marby | F | - |
University of Uppsala
| 3 Jahre |
| Georg Praeauer | M | - |
University of Uppsala
| 2 Jahre |
| Andreas Wagner | M | - |
University of Uppsala
| 2 Jahre |
| Gabriella Ardbo | F | 31 |
University of Uppsala
| 4 Jahre |
| Anders Bylock | M | 70 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 4 Jahre |
| Hjalmar Ek | M | - |
University of Uppsala
| 3 Jahre |
| Ulrika Kopp | F | - |
University of Uppsala
| 5 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Schweden | 86 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Johan Lindh
- Persönliches Netzwerk
